Find Funding Opportunities

This FOA is issued as an initiative of the NIH Blueprint for Neuroscience Research. The Neuroscience Blueprint is a collaborative framework through which 16 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see http://neuroscienceblueprint.nih.gov/).

This FOA solicits Research Education Grant (R25) applications from institutions/organizations that propose to support the development and/or implementation of programs that relate to research education and training of clinical residents and fellows to foster careers as physician-scientists. The PD/PI (see below) must have a staff appointment in a Department of Neurology, Neurosurgery or Pathology and participants in the research education program must be residents or fellows in neurology, neurosurgery, neuropathology or neuroradiology (see Eligible Individuals). The NIH recognizes a unique and compelling need to promote diversity in the biomedical, behavioral, clinical and social sciences research workforce. Accordingly, the NIH continues to encourage institutions to diversify their student and faculty populations and thus to increase the participation of individuals currently underrepresented in the biomedical, clinical, behavioral, and social sciences such as: individuals from underrepresented racial and ethnic groups, and individuals with disabilities. PD/PIs are encouraged to consider participants from diverse backgrounds for this funding opportunity. (see Recruitment and Retention Plan to Enhance Diversity).

This FOA solicits Research Project Grant (R01) applications from institutions/organizations proposing exceptionally innovative research on novel hypotheses or difficult problems, solutions to which would have an extremely high impact on biomedical or biobehavioral research in the epilepsies. This FOA is for support of new projects, not continuation of projects that have already been initiated. It does not support pilot projects, i.e., projects of limited scope that are designed primarily to generate data that will enable the PD/PI to seek other funding opportunities. Interventional clinical trials are also not appropriate for this FOA.

The purpose of this funding opportunity announcement (FOA), issued by NINDS, is to invite applications for a study of candidate biomarkers in Spinal Muscular Atrophy (SMA). The study will be done using the NeuroNEXT infrastructure (as established in response to RFA-NS-11-009, RFA-NS-11-010, RFA-NS-11-008) along with ad hoc clinical sites as appropriate. This is a milestone-driven cooperative agreement program involving participation of NIH staff in the development of the project plan and monitoring of research progress.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Deafness and Other Communication Disorders (NIDCD), the National Institute of Environmental Health Sciences (NIEHS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS) invite new (type 1) and renewal (type 2) applications for the Autism Centers of Excellence: Networks Program, hereafter termed ACE Networks. Each ACE Network will consist of a multi-site project focusing on a specific topic of research for R01 support through this FOA. The ACE Networks will focus on supporting the broad research goals of the Interagency Coordinating Committee Strategic Plan for ASD Research (http://iacc.hhs.gov/strategic-plan/2011/index.shtml). Each ACE Network will submit one R01 application that includes subawardss to the collaborating sites. A companion FOA (RFA-HD-12-195) invites applications for ACE Centers supported by the P50 mechanism.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), the National Institute on Deafness and Other Communication Disorders (NIDCD), the National Institute of Environmental Health Sciences (NIEHS), the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS) invite new (type 1) and competitive renewal (type 2) applications for the Autism Centers of Excellence: Centers Program, hereafter termed ACE Centers. ACE Centers will focus on supporting the broad research goals of the 2011 Interagency Autism Coordinating Committee Strategic Plan for ASD Research (http://iacc.hhs.gov/strategic-plan/2011/index.shtml. The P50 mechanism allows for integrative, multi-disciplinary, coordinated programs of research that demonstrate cohesion and synergy across research subprojects and cores. A companion FOA (RFA-HD-12-196) invites applications for ACE Networks supported by the R01 mechanism.

The National Heart, Lung, and Blood Institute (NHLBI) and National Institute of Neurological Disorders and Stroke (NINDS) invite research grant applications focusing on effective interventions that will provide sound scientific evidence for expanding sustainable blood pressure prevention and control programs in low and middle income countries (LMICs) at the local, regional, and national level.

This funding opportunity announcement (FOA) encourages Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) that propose the development of broadly applicable research tools that address the core technical challenges in proteomics and glycomics. This includes but is not restricted to robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies. Technologies that address the unique needs of glycomics and clinical proteomics, described in Section II.I.1 (Research Objectives) are of particular interest.

This funding opportunity announcement (FOA) encourages Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) that propose the development of broadly applicable research tools that address the core technical challenges in proteomics and glycomics. This includes but is not restricted to robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies. Technologies that address the unique needs of glycomics and clinical proteomics, described in Section II.I.1 (Research Objectives) are of particular interest.

This FOA provides for planning grants for clinical trials related to type 1 diabetes. It is expected that these planning grants will lead to clinical trials to test interventions designed to improve glycemic control and/or to treat or reduce diabetes complications. The intent of this initiative is to improve the management and treatment of individuals with type 1 diabetes in the United States. If successful, the results of the future clinical trials should be of practical importance to clinical management and applicable immediately. The purpose of this FOA is not to validate new technologies or test new therapeutics.